Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23768365 | 0.85 | SOAT1 (0.49) | HCAR3TLR8SOAT1 | |
| SCHEMBL12895618 | 0.83 | HCAR3 (0.39) | HCAR3SMN1; SMN2ALDH1A1TP53NPC1 | |
| SCHEMBL1752801 | 0.82 | SYK (0.41) | SMN1; SMN2HPGDALDH1A1KDM4EHDAC1 | |
| SCHEMBL20037454 | 0.82 | IL1B (0.45) | HPGDALDH1A1LMNARAB9AKDM4E | |
| SCHEMBL15382053 | 0.79 | HCAR3 (0.46) | HCAR3SMN1; SMN2HPGDALDH1A1TP53 | |
| SCHEMBL8046837 | 0.79 | HRH3 (0.45) | SMN1; SMN2HPGDALDH1A1LMNATP53 | |
| SCHEMBL10356814 | 0.79 | CYP2C19 (0.50) | — | |
| SCHEMBL4889623 | 0.78 | HCAR3 (0.41) | HCAR3SMN1; SMN2HPGDALDH1A1LMNA | |
| SCHEMBL27401621 | 0.78 | MAPT (0.50) | HCAR3SMN1; SMN2HPGDALDH1A1LMNA | |
| SCHEMBL16136909 | 0.76 | PIM1 (0.50) | SMN1; SMN2HPGDALDH1A1PIM1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080032975-A1 | Substituted Fused Pyrroleoximes and Fused Pyrazoleoximes | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2008-02-07 | — | — | US | disclosed |
| US-7282498-B2 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NEUROGEN CORPORATION (US) | 2007-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032975-A1 | Substituted Fused Pyrroleoximes and Fused Pyrazoleoximes | NPSR1, GABRE, CHRNE | HCAR3 528/4885SMN1; SMN2 848/4885HPGD 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.